05:44 PM EDT, 05/22/2025 (MT Newswires) -- Verastem ( VSTM ) said late Thursday that the metastatic pancreatic ductal adenocarcinoma patients treated with avutometinib or Avmapki plus defactinib in combination with standard-of-care chemotherapy achieved an overall response rate of 83% as of April 25.

Under the RAMP 205 phase 1/2 trial, the company said 60 patients were treated in one of five dose regimens with the combination of avutometinib and defactinib with gemcitabine and nab-paclitaxel in frontline metastatic PDAC.

The trial showed positive safety and efficacy results, with adverse events remaining generally consistent with the previously announced safety and tolerability profile, the company said.

Verastem ( VSTM ) said it plans to register a phase 3 front-line metastatic PDAC trial, expected to start in 2026.